Axon Enterprise, Inc $AXON Shares Sold by Cookson Peirce & Co. Inc.

Key Points

• Cookson Peirce & Co. Inc. reduced its holdings in Axon Enterprise by 2.3%, now owning 46,394 shares worth approximately $38.4 million.
• Axon Enterprise reported $2.12 earnings per share for its latest quarter, exceeding analysts' estimates by $0.58, and experienced a 32.6% increase in year-over-year revenue.
• The stock currently holds a consensus rating of "Moderate Buy" from 14 analysts, with an average target price of $841.64.

Cookson Peirce & Co. Inc. trimmed its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 2.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 46,394 shares of the biotechnology company's stock after selling 1,082 shares during the period. Axon Enterprise accounts for 1.7% of Cookson Peirce & Co. Inc.'s portfolio, making the stock its 19th biggest position. Cookson Peirce & Co. Inc. owned approximately 0.06% of Axon Enterprise worth $38,411,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of Axon Enterprise by 2.2% during the first quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock worth $4,540,005,000 after purchasing an additional 185,571 shares during the period. Alliancebernstein L.P. raised its holdings in shares of Axon Enterprise by 15.9% during the first quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company's stock worth $675,812,000 after purchasing an additional 175,890 shares during the period. Westfield Capital Management Co. LP raised its holdings in shares of Axon Enterprise by 29.8% during the first quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock worth $487,977,000 after purchasing an additional 212,931 shares during the period. Northern Trust Corp raised its holdings in shares of Axon Enterprise by 1.2% during the first quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company's stock worth $381,692,000 after purchasing an additional 8,794 shares during the period. Finally, Jennison Associates LLC raised its holdings in shares of Axon Enterprise by 23,203.7% during the first quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company's stock worth $322,961,000 after purchasing an additional 611,418 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AXON. Wolfe Research started coverage on shares of Axon Enterprise in a report on Monday, July 7th. They set an "outperform" rating on the stock. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a report on Tuesday, August 5th. Zacks Research cut shares of Axon Enterprise from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 2nd. Craig Hallum raised shares of Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price objective on the stock in a report on Tuesday, August 5th. Finally, Piper Sandler started coverage on shares of Axon Enterprise in a report on Tuesday, September 23rd. They issued an "overweight" rating and a $893.00 price objective on the stock. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of "Moderate Buy" and an average target price of $841.64.

Axon Enterprise Stock Performance

Shares of AXON opened at $707.04 on Wednesday. The firm has a 50-day moving average price of $735.50 and a 200 day moving average price of $720.82. The firm has a market capitalization of $55.51 billion, a PE ratio of 174.58, a P/E/G ratio of 26.53 and a beta of 1.41. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 52-week low of $422.38 and a 52-week high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise's revenue was up 32.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In related news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $831.29, for a total value of $8,312,900.00. Following the completion of the transaction, the chief executive officer owned 3,053,982 shares in the company, valued at $2,538,744,696.78. This represents a 0.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Jeffrey C. Kunins sold 7,891 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $750.10, for a total transaction of $5,919,039.10. Following the completion of the transaction, the insider owned 144,538 shares of the company's stock, valued at $108,417,953.80. This represents a 5.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,932 shares of company stock worth $45,115,616 over the last ninety days. Insiders own 5.70% of the company's stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.